http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( B Massetto ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( S Fung ),( P Kwan ),( A Horban ),( M Pelemis ),( P Husa ),( H W Hann ),( Jf Flaherty ),( B Massetto ),( P Dinh ),( A Corsa ),( K Kitrinos ),( Jg Mchutchison ),( M Fabri ),( E Gane ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: Efficacy and safety of tenofovir DF (TDF) have been demonstrated over 6 years in pivotal HBV studies, but have yet to be established in lamivudine-resistant (LAM-R) patients in a prospective, randomized trial. Methods: Phase 3b, double-blind, randomized (1:1) comparison of TDF and emtricitabine (FTC)/TDF in chronic HBV patients on LAM at screening with HBV DNA ≥103 IU/mL and documented LAM-R (rtM204V/I±rtL180M; INNO-LiPA HBV v2/ v3). Patients were stratified by ALT (≥ or <2×ULN) and HBeAg status. Efficacy and safety, including bone mineral density (BMD) monitoring by DXA were assessed over 96 weeks. Results: Of 280 randomized and treated patients, 133/141 (94%) and 125/139 (90%) in TDF and FTC/TDF groups completed 96 weeks. Groups were well matched: mean age 47 years, 75% males, 34% Asian, 47% HBeAg+, 42% ALT <ULN; HBV genotypes: 22% A, 14% B, 19% C, and 45% D. By ITT analysis, missing=failure, 89% and 86% receiving TDF and FTC/TDF, respectively, had HBV DNA <400 copies/mL at Week 96 (P =0.43); 70% in each arm had normal ALT. HBeAg loss was observed in 10/65 (15%) and 9/68 (13%) in TDF and FTC/TDF arms, respectively. One patient (FTC/TDF) had HBsAg loss without seroconversion. Both treatments were well tolerated with 1% (3/280) discontinuing for adverse event (1 TDF, 2 FTC/TDF). No patients had confirmed increase in serum creatinine of ≥0.5 mg/dL, and 1% (2 TDF) had serum phosphorus <2 mg/dL. BMD of spine and hip revealed no clinically relevant bone loss, and there were no non-traumatic fractures reported. No TDF resistance was detected through 96 weeks. Conclusions: A high rate of HBV DNA suppression with no detectable TDF resistance was achieved with TDF monotherapy in LAM?R patients through 96 weeks. TDF was safe and well tolerated, with a low rate of renal events and no evidence of clinically relevant bone loss.
-
( Chun-Jen Liu ),( Wan-Long Chuang ),( I-Shyan Sheen ),( Horng-Yuan Wang ),( Chi-Yi Chen ),( Kuo-Chih Tseng ),( Ting-Tsung Chang ),( Benede tta Massetto ),( Jenny Yang ),( Gregory Camus ),( Fangqiu Zh 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Patients co-infected with HCV and HBV have more rapid progression and worse outcomes than mono-infected patients. Taiwan has among the highest prevalence of chronic HCV/HBV coinfection in Southeast Asia. This study evaluated the safety and efficacy of an all-oral treatment with ledipasvir(LDV)/sofosbuvir(SOF) for 12 weeks in chronic HCV and HBV coinfection. Methods: Patients with or without compensated cirrhosis chronic HCV GT1/GT2 and HBV (HBsAg+) treatment naïve were enrolled into open-label, receiving LDV 90 mg/SOF 400 mg(QD) for 12 weeks. The primary efficacy endpoint is SVR12. HBV DNA was monitored at all study visits and it will be monitored for 2 years post-treatment. Results: A total of 111 patients (68[61%] with GT1 and 43[39%] with GT2) were enrolled and treated. The majority were female(62%), treatment naive(67%), and non-cirrhotic(85%), with a mean age of 55 years and mean BMI of 24.5kg/m2. All but one was HBeAg negative. Mean baseline HBV DNA was 2.1 log10IU/mL. SVR4 was 100%(111/111). The mean change in HBV DNA ranged from -0.06 log10IU/mL at week 1 to +0.49 log10IU/mL at follow-up visit 4; HBV DNA kinetics are shown in Fig 1. 60(54%) patients had an increase in HBV DNA> 10 x BL or became HBV DNA > LLOQ. No patients had ALT ≥ 2 X baseline. No patients discontinued treatment due to adverse events (AEs). Three patients had serious AEs(optic neuritis, post procedural bleeding and duodenal ulcer bleeding; none was considered drug related). Conclusions: In chronic HCV/HBV infection patients, LDV/SOF for 12 weeks resulted in an SVR4 rate of 100%. Although most patients had an increase in HBV DNA during treatment, this was not associated with ALT elevations ≥2 X baseline, and no patients started HBV therapy to date. This all-oral, interferon-free regimen was well tolerated, supporting its potential as a treatment option for HCV/HBV co-infected patients.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
